Search
Research
Implications of Non-Specific Effects for Testing, Approving, and Regulating VaccinesThe current framework for testing and regulating vaccines was established before the realization that vaccines, in addition to their effect against the vaccine-specific disease, may also have "non-specific effects" affecting the risk of unrelated diseases. Accumulating evidence from epidemiological studies shows that vaccines in some situations can affect all-cause mortality and morbidity in ways that are not explained by the prevention of the vaccine-targeted disease.
Research
Correlates of immunity to Group A Streptococcus: a pathway to vaccine developmentUnderstanding immunity in humans to Group A Streptococcus (Strep A) is critical for the development of successful vaccines to prevent the morbidity and mortality attributed to Strep A infections. Despite decades of effort, no licensed vaccine against Strep A exists and immune correlates of protection are lacking; a major impediment to vaccine development.

News & Events
The good oil on immunisationAs a new parent or parent-to-be, you will be faced with many important decisions about your health and the health of your child, including immunisation.
News & Events
National Indigenous Immunisation Research WorkshopYou are invited to register to attend the National Indigenous Immunisation Research Workshop 2013: lessons learnt and future directions Workshop.
News & Events
The science of immunisation: Questions and answersCommon myths about immunisation have been laid to rest in a new booklet written by top immunologists and published by the Australian Academy of Science.

News & Events
Immunisation advice before, during and after pregnancyAre you pregnant or planning to have a baby? There are important vaccinations that you should consider to protect your health and the health of your baby.

News & Events
Warm Welcome for the Neonatal Infection and Immunity TeamClinical Professor Tobias Strunk, Dr Andrew Currie and their Neonatal Infection and Immunity Team have become the newest members of the Wesfarmers Centre of Vaccines and Infectious Diseases.
Research
Pertussis burden and acellular pertussis vaccine effectiveness in high risk childrenPertussis hospitalisation is more common among infants born prematurely, who have significant comorbidities, or are Indigenous, but acellular pertussis (aP) vaccine effectiveness (VE) estimates in these sub-groups are lacking. We measured aP VE by Indigenous status, and policy-relevant categories of prematurity and comorbidity, in a population-based Australian cohort.
Research
Longitudinal, population-based cohort study of prenatal influenza vaccination and influenza infection in childhoodInfluenza vaccination is recommended to protect mothers and their infants from influenza infection. Few studies have evaluated the health impacts of in utero exposure to influenza vaccine among children more than six months of age.
Research
An eight-plex immunoassay for Group A streptococcus serology and vaccine developmentGroup A Streptococcus (GAS) is a major human pathogen responsible for superficial infections through to life-threatening invasive disease and the autoimmune sequelae acute rheumatic fever (ARF). Despite a significant global economic and health burden, there is no licensed vaccine available to prevent GAS disease. Several pre-clinical vaccines that target conserved GAS antigens are in development.